방사선 종양학 시장 규모, 점유율 및 동향 분석 보고서 : 치료법별, 기술별, 용도별, 타겟 고객별, 지역별 및 부문별 예측(2026-2033년)

Radiation Oncology Market Summary

The global radiation oncology market size was estimated at USD 14.03 billion in 2025 and is projected to reach USD 33.09 billion by 2033, growing at a CAGR of 11.42% from 2026 to 2033. This growth is driven by the rising prevalence of cancer and increasing demand for effective, targeted treatment options.

Advancements in technologies such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and proton therapy are enhancing treatment precision and outcomes. In addition, expanding healthcare infrastructure, growing adoption in emerging markets, and increased investments in oncology care are further supporting market expansion worldwide.

The global radiation oncology industry is primarily driven by the rising incidence of cancer worldwide, which continues to place significant pressure on healthcare systems to expand treatment capacity and adopt advanced therapeutic solutions. Factors such as aging populations, sedentary lifestyles, tobacco use, and environmental exposures have contributed to a steady increase in cancer diagnoses, making radiation therapy a critical component of modern oncology care. According to the World Health Organization in 2022, there were approximately 9.7 million cancer-related deaths globally, with 53.5 million people living within five years of a diagnosis. The organization also highlighted that 1 in 5 individuals develop cancer during their lifetime, with major cancers such as lung (2.5 million cases), breast (2.3 million), and colorectal (1.9 million) driving substantial demand for effective treatment technologies, including radiation therapy.

The growing burden of cancer, including a significant proportion linked to preventable risk factors, is further accelerating the adoption of radiation oncology solutions. In February 2026, the World Health Organization reported that around 37% of global cancer cases, equivalent to 7.1 million cases, were associated with modifiable risk factors such as tobacco use, alcohol consumption, obesity, and environmental exposures. This rising prevalence of lifestyle-related cancers is increasing the need for precise and effective treatment modalities. Radiation therapy plays a crucial role across multiple stages of cancer management, including curative, adjuvant, neoadjuvant, and palliative care, thereby expanding its utilization across hospitals and specialized cancer centers globally. The increasing number of cancer cases is also evident in major markets such as the U.S., where the American Association for Cancer Research estimated 2,041,910 new cancer cases and 618,120 deaths in 2025, highlighting the growing reliance on advanced oncology treatments.

Technological advancements in radiation therapy are significantly transforming the market by improving treatment precision, efficiency, and patient outcomes. Innovations such as image guided radiotherapy (IGRT), intensity modulated radiotherapy (IMRT), stereotactic radiosurgery (SRS), and proton therapy enable highly targeted radiation delivery while minimizing damage to surrounding healthy tissues. For instance, in March 2026, researchers introduced an AI-based radiotherapy framework (AIRT) capable of generating prostate treatment plans in under one second using a single NVIDIA A100 GPU, demonstrating the growing integration of artificial intelligence in treatment planning. Similarly, in March 2025, Elekta showcased its AI-powered adaptive CT-Linac platform, enabling real-time treatment adjustments, while in September 2024, a compact proton therapy center developed by Mevion Medical Systems was announced in the U.S., reflecting the ongoing shift toward more precise and space-efficient radiotherapy solutions.

In addition to technological progress, increasing investments in oncology infrastructure are playing a vital role in supporting market growth. Governments and private healthcare providers are actively expanding radiotherapy capacity through funding initiatives, equipment upgrades, and the development of specialized cancer centers. For instance, in June 2025, the UK government announced an investment of about USD 88 million to replace linear accelerator machines across 28 hospitals, while international efforts such as the International Atomic Energy Agency's collaboration in February 2025 aimed to establish radiotherapy infrastructure in underserved regions like the Democratic Republic of the Congo. Private sector contributions, including NTPC Limited's USD 2.8 million investment to upgrade radiotherapy services in India, further highlight the growing commitment to strengthening cancer care infrastructure. These combined efforts, along with improved screening and early diagnosis, are expanding access to radiation therapy and driving sustained growth in the global radiation oncology industry.

Global Radiation Oncology Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global radiation oncology market report based on treatment, technology, application, target customer, and region:

• Treatment Outlook (Revenue, USD Million, 2021 - 2033)
• External Beam Radiation Therapy (EBRT)
  • Linear Accelerators (LINAC)
  • Stereotactic Radiosurgery (SRS) Systems
  • Tomotherapy Systems
  • Particle Beam Therapy
  • Proton Therapy
  • Heavy-Ion Therapy
• Internal Beam Radiation Therapy
  • Brachytherapy
  • Low-Dose Rate (LDR) Brachytherapy
  • Seeds
  • High-Dose Rate (HDR) Brachytherapy
  • Afterloaders
  • Applicators
  • Electronic Brachytherapy
• Systemic Targeted Radiation Therapy
  • Radioligand Therapy (RLT)
  • Beta-Emitting Radioligand Therapies
  • Alpha-Emitting Radioligand Therapies
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Image-Guided Radiotherapy (IGRT)
  • Motion Tracking / Real-Time Tumor Tracking
  • Other
• Intensity-Modulated Radiotherapy (IMRT)
• Volumetric Modulated Arc Therapy (VMAT)
• 3D Conformal Radiation Therapy (3D-CRT)
• Stereotactic Radiotherapy (SRS / SBRT)
• Proton Beam Delivery Technology
• Heavy-Ion Delivery Technology
• Adaptive Radiotherapy
• Upright Beam Delivery Technology
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• External Beam Radiation Therapy (EBRT)
  • Prostate Cancer
  • Breast Cancer
  • Lung Cancer
  • Head & Neck Cancer
  • Colorectal Cancer
  • Central Nervous System (CNS) Tumors
  • Others (e.g., Pediatric Cancers)
• Internal Beam Radiation Therapy
  • Prostate Cancer
  • Gynecological Cancer
  • Cervical Cancer
  • Breast Cancer
  • Others (e.g., Penile Cancer)
• Radioligand Therapy Applications
  • Prostate Cancer
  • Neuroendocrine Tumors
  • Thyroid Cancer
  • Others (e.g., Hematologic Malignancies)
• Target Customer Outlook (Revenue, USD Million, 2021 - 2033)
• Academic & Research Cancer Centers
• Government & Public Tertiary Hospitals
• Private Oncology Chains
• Specialty Proton / Particle Therapy Centers
• Nuclear Medicine & Theranostics Centers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwai

Table of Contents

Chapter 1. Radiation Oncology Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Method
    • 1.1.1.2. Technology Segment
    • 1.1.1.3. Application Segment
    • 1.1.1.4. Target Customer
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Radiation Oncology Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Treatment Snapshot
• 2.3. Technology Snapshot
• 2.4. Application Snapshot
• 2.5. Target Customer Snapshot
• 2.6. Competitive Landscape Snapshot

Chapter 3. Radiation Oncology Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
• 3.5. Market Restraint Analysis
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Radiation Oncology Market: Treatment Estimates & Trend Analysis

• 4.1. Global Radiation Oncology Market: Treatment Dashboard
• 4.2. Global Radiation Oncology Market: Treatment Movement Analysis
• 4.3. Global Radiation Oncology Market by treatment, Revenue
• 4.4. External Beam Radiation Therapy (EBRT)
  • 4.4.1. External Beam Radiation Therapy (EBRT) market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Linear Accelerators (LINAC)
    • 4.4.2.1. Linear Accelerators (LINAC) market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. Stereotactic Radiosurgery (SRS) Systems
    • 4.4.3.1. Stereotactic Radiosurgery (SRS) Systems market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.4. Tomotherapy Systems
    • 4.4.4.1. Tomotherapy Systems market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.5. Particle Beam Therapy
    • 4.4.5.1. Particle Beam Therapy market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5.2. Proton Therapy
      • 4.4.5.2.1. Proton Therapy market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5.3. Heavy-Ion Therapy
      • 4.4.5.3.1. Heavy-Ion Therapy market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Internal Beam Radiation
  • 4.5.1. Internal Beam Radiation Therapy market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.2. Brachytherapy
  • 4.5.3. Brachytherapy market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.4. Low-Dose Rate (LDR) Brachytherapy
    • 4.5.4.1. Low-Dose Rate (LDR) Brachytherapy market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.4.2. Seeds
      • 4.5.4.2.1. Seeds market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.5. High-Dose Rate (HDR) Brachytherapy
    • 4.5.5.1. High-Dose Rate (HDR) Brachytherapy market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.5.2. Afterloaders
      • 4.5.5.2.1. Afterloaders market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.5.3. Applicators
      • 4.5.5.3.1. Applicators market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.6. Electronic Brachytherapy
  • 4.5.7. Electronic Brachytherapy market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Systemic Targeted Radiation Therapy
  • 4.6.1. Systemic Targeted Radiation Therapy market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6.2. Radioligand Therapy (RLT)
    • 4.6.2.1. Radioligand Therapy (RLT) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.6.2.2. Beta-Emitting Radioligand Therapies
      • 4.6.2.2.1. Beta-Emitting Radioligand Therapies market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.6.2.3. Alpha-Emitting Radioligand Therapies
      • 4.6.2.3.1. Alpha-Emitting Radioligand Therapies market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Radiation Oncology Market: Technology Estimates & Trend Analysis

• 5.1. Global Radiation Oncology Market: Technology Dashboard
• 5.2. Global Radiation Oncology Market: Technology Movement Analysis
• 5.3. Global Radiation Oncology Market by Technology, Revenue
• 5.4. Image-Guided Radiotherapy (IGRT)
  • 5.4.1. Image-Guided Radiotherapy (IGRT) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Motion Tracking / Real-Time Tumor Tracking
    • 5.4.2.1. Motion Tracking / Real-Time Tumor Tracking market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.3. Other
    • 5.4.3.1. Other market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Intensity-Modulated Radiotherapy (IMRT)
  • 5.5.1. Intensity-Modulated Radiotherapy (IMRT) market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Volumetric Modulated Arc Therapy (VMAT)
  • 5.6.1. Volumetric Modulated Arc Therapy (VMAT) market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. 3D Conformal Radiation Therapy (3D-CRT)
  • 5.7.1. 3D Conformal Radiation Therapy (3D-CRT) market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Stereotactic Radiotherapy (SRS / SBRT)
  • 5.8.1. Stereotactic Radiotherapy (SRS / SBRT) market estimates and forecasts 2021 to 2033 (USD Million)
• 5.9. Proton Beam Delivery Technology
  • 5.9.1. Proton Beam Delivery Technology market estimates and forecasts 2021 to 2033 (USD Million)
• 5.10. Heavy-Ion Delivery Technology
  • 5.10.1. Heavy-Ion Delivery Technology market estimates and forecasts 2021 to 2033 (USD Million)
• 5.11. Adaptive Radiotherapy
  • 5.11.1. Adaptive Radiotherapy market estimates and forecasts 2021 to 2033 (USD Million)
• 5.12. Upright Beam Delivery Technology
  • 5.12.1. Upright Beam Delivery Technology market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Radiation Oncology Market: Application Estimates & Trend Analysis

• 6.1. Global Radiation Oncology Market: Application Dashboard
• 6.2. Global Radiation Oncology Market: Application Movement Analysis
• 6.3. Global Radiation Oncology Market by Application, Revenue
• 6.4. External Beam Radiation Therapy (EBRT)
  • 6.4.1. External Beam Radiation Therapy (EBRT) market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Diagnostic laboratories
    • 6.4.2.1. Diagnostic laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. Prostate Cancer
    • 6.4.3.1. Prostate Cancer market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.4. Breast Cancer
    • 6.4.4.1. Breast Cancer market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.5. Lung Cancer
    • 6.4.5.1. Lung Cancer market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.6. Head & Neck Cancer
    • 6.4.6.1. Head & Neck Cancer market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.7. Colorectal Cancer
    • 6.4.7.1. Colorectal Cancer market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.8. Central Nervous System (CNS) Tumors
    • 6.4.8.1. Central Nervous System (CNS) Tumors market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.9. Others (e.g., Pediatric Cancers)
    • 6.4.9.1. Others (e.g., Pediatric Cancers) market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Internal Beam Radiation Therapy
  • 6.5.1. Internal Beam Radiation Therapy market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.2. Prostate Cancer
    • 6.5.2.1. Prostate Cancer market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.3. Gynecological Cancer
    • 6.5.3.1. Gynecological Cancer market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.4. Cervical Cancer
    • 6.5.4.1. Cervical Cancer market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.5. Breast Cancer
    • 6.5.5.1. Breast Cancer market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.6. Others (e.g., Penile Cancer)
    • 6.5.6.1. Others (e.g., Penile Cancer) market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Radioligand Therapy Applications
  • 6.6.1. Radioligand Therapy Applications market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.2. Prostate Cancer
    • 6.6.2.1. Prostate Cancer market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.3. Neuroendocrine Tumors
    • 6.6.3.1. Neuroendocrine Tumors market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.4. Thyroid Cancer
    • 6.6.4.1. Thyroid Cancer market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.5. Others (e.g., Hematologic Malignancies)
    • 6.6.5.1. Others (e.g., Hematologic Malignancies) market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Radiation Oncology Market: Target Customer Estimates & Trend Analysis

• 7.1. Global Radiation Oncology Market: Target Customer Dashboard
• 7.2. Global Radiation Oncology Market: Target Customer Movement Analysis
• 7.3. Global Radiation Oncology Market by Target Customer, Revenue
• 7.4. Academic & Research Cancer Centers
  • 7.4.1. Academic & Research Cancer Centers market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Government & Public Tertiary Hospitals
  • 7.5.1. Government & Public Tertiary Hospitals market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Private Oncology Chains
  • 7.6.1. Private Oncology Chains market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Specialty Proton / Particle Therapy Centers
  • 7.7.1. Specialty Proton / Particle Therapy Centers market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. Nuclear Medicine & Theranostics Centers
  • 7.8.1. Nuclear Medicine & Theranostics Centers market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Radiation Oncology Market: Regional Estimates & Trend Analysis by Product Type, Technology, and Application

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Mexico
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2025
  • 9.3.4. Varian Medical Systems, Inc. (Siemens Healthineers)
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Elekta AB
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Accuray Incorporated
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. IBA (Ion Beam Applications)
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. BD (Becton, Dickinson and Company)
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Curium
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Panacea Medical Technologies
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Mevion Medical Systems
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Canon Medical Systems Corporation
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Sumitomo Heavy Industries, Ltd.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives